Goldman Sachs Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $20

Benzinga · 10/25 16:17
Goldman Sachs analyst Salveen Richter maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and lowers the price target from $31 to $20.